 |
|
| Systematic (IUPAC) name | |
|---|---|
|
4-(3-Hydroxy-8-aza-bicyclo[3.2.1]octyl)-naphthalene-1-carbonitrile
|
|
| Identifiers | |
| PubChem | CID: 11673547 |
| Chemical data | |
| Formula | C18H18N2O |
| Molecular mass | 278.348 g/mol |
|
|
 (what is this?) (verify) |
|
AC-262,356 is a drug developed by Acadia Pharmaceuticals which acts as a selective androgen receptor modulator. It acts as a partial agonist for the androgen receptor with a Ki of 5nM, and no significant affinity for any other receptors tested. In animal studies it produced a maximal effect of around 66% of the anabolic action of testosterone, but only around 27% of its potency as an androgen.[1]
References[edit]
- ^ Piu, F; Gardell, LR; Son, T; Schlienger, N; Lund, BW; Schiffer, HH; Vanover, KE; Davis, RE; Olsson, R; Bradley, SR (2008). "Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator". The Journal of Steroid Biochemistry and Molecular Biology 109 (1–2): 129–37. doi:10.1016/j.jsbmb.2007.11.001. PMID 18164613.